Company / Working Capital
Sana Biotechnology, Inc. Working Capital History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$115.4M
FY2024
5-year range
$115.4M / $458.9M
FY2020-FY2024
Trend
-22.6%
vs FY2023
Sector context
#191 of 213
Health Care
What the data says
Among 213 Health Care companies, Sana Biotechnology, Inc. is in the bottom 10% for working capital. Working Capital has declined for 3 consecutive years, from $459M in FY2021 to $115M in FY2024.
Based on SEC 10-K filings.
$115M in FY2024 with a 3-year CAGR of -36.9%.
Declined from $333M to $115M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -36.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 213This company $115.4M Sector average $934.6M
▼
-87.7% below sector average
Key checks
Key Insights
- Sana Biotechnology, Inc.'s working capital has declined for 3 consecutive years.
- 3-year CAGR of -36.9%, indicating a declining trend.
- In FY2024, working capital decreased 22.6% year-over-year.
- Ranks #191 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $115.4M | -22.6% |
| FY2023 | $149.0M | -55.2% |
| FY2022 | $332.9M | -27.4% |
| FY2021 | $458.9M | +30.0% |
| FY2020 | $353.0M | - |
| FY2019 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026